ELAN
NYSEElanco Animal Health Incorporated
Price$23.61-0.83 (-3.40%)
2026-03-042026-06-05
News · 26 weeks112+40%
2025-12-142026-06-07
Mix5590d
- Insider34(62%)
- Other12(22%)
- SEC Filings5(9%)
- Earnings2(4%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- PRElanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World ScrewwormCompany offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today reaffirms its commitment to providing veterinarians, livestock produ
- PRNew Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry ResilienceINDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry. According to Elanco's latest survey of 1,409 U.S. pet owners conducted May 29-31, even with rising costs across spending categories including higher gas prices, pet health and wellness remain an absolute priority for pet owners as a protected budget item.Stable Expectations for Pet Owner Spend:
- INSIDERSEC Form 4 filed by EVP and CFO Vanhimbergen Robert M4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by Officer Modi Rajeev A.4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N4 - Elanco Animal Health Inc (0001739104) (Issuer)
- SECSEC Form SD filed by Elanco Animal Health IncorporatedSD - Elanco Animal Health Inc (0001739104) (Filer)
- SECElanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Elanco Animal Health Inc (0001739104) (Filer)
- INSIDERDirector Scots-Knight Denise was granted 16,874 shares, increasing direct ownership by 19% to 105,588 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Kurzius Lawrence Erik was granted 16,874 shares, increasing direct ownership by 13% to 148,647 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Mcdonald Kirk P was granted 16,874 shares, increasing direct ownership by 19% to 105,588 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Herendeen Paul was granted 16,874 shares, increasing direct ownership by 20% to 101,687 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Kochevar Deborah Turner was granted 4,678 shares, increasing direct ownership by 5% to 94,392 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Hoover R David was granted 4,678 shares, increasing direct ownership by 4% to 111,451 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Harrington Michael J was granted 16,874 shares, increasing direct ownership by 15% to 126,451 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Anand Kapila K was granted 16,874 shares, increasing direct ownership by 18% to 111,847 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Ma Stacey was granted 16,874 shares, increasing direct ownership by 131% to 29,727 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Garcia Art A was granted 16,874 shares, increasing direct ownership by 18% to 108,152 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDEROfficer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERPRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Vanhimbergen Robert M4 - Elanco Animal Health Inc (0001739104) (Issuer)
- PRElanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology MarketPhased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics todayBefrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux, Penelope and Zephyr, the first early experience patients to receive Befrena and follow their jo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health IncorporatedSCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
- PRElanco to Participate in Upcoming Investor ConferencesINDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference at 8:00 a.m. ET.On Tuesday, June 2, Jeff Simmons, president and CEO will present at the William Blair 46th Annual Growth Stock Conference at 3:20 p.m. CT.Live audio webcasts will be available in the "Events and Presentations
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health IncorporatedSCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
- PRElanco Animal Health Reports First Quarter 2026 ResultsRaising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y
ELAN FAQ
7 questionsWhat does Elanco Animal Health Incorporated do?
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and...Where does ELAN stock trade?
Elanco Animal Health Incorporated (ELAN) is listed on NYSE.What sector and industry is ELAN in?
Elanco Animal Health Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Elanco Animal Health Incorporated go public?
Elanco Animal Health Incorporated (ELAN) completed its IPO in 2018.What are analysts saying about ELAN?
Elanco Animal Health Incorporated has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $3000.00 price target on 2026-04-15. Recent price targets range from $1800.00 to $3000.00.What companies are similar to ELAN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ELAN side-by-side with any of them on Quantisnow.How can I track ELAN on Quantisnow?
Quantisnow aggregates Elanco Animal Health Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELAN to receive live email and push alerts on every new disclosure.